Less than three years after launching its breast cancer drug Piqray, Novartis has received an FDA approval for the treatment in a rare condition PROS. This drug, named Vijoice, a PI3K inhibitor to treat PIK3CA-related overgrowth spectrum (PROS), an umbrella term for the rare condition that causes blood vessel abnormalities and overgrowth of tissue that can present in a variety of ways.
Click here to view the entire article.